STUDresearch · Peptide
Berobenatide
Also known as
PF-08653944 · PF’3944 · MET-097i (Metsera name before Pfizer) · Pfizer monthly GLP-1
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
SubQ (trials)
Metabolic / GLP-1 class
Systemic ultra-long GLP-1 peptide — weekly titration then monthly maintenance in VESPER.
What people say
Berobenatide is Pfizer's investigational, long-acting GLP-1 receptor agonist, studied for appetite and weight management as subcutaneous weekly and monthly treatment. It is not an approved product or a dual agonist.
Doses people talk about
Weekly and monthly regimens belong to different VESPER designs. The summary keeps them separate and does not turn study transitions into personal instructions.
How it may feel
A blinded weekly-trial participant described less food noise and earlier satiety during the first five weeks, with occasional fullness and heartburn after fatty meals. Blinding prevents attribution to active drug.
Weekly Phase 2b arms0.4–2.4 mg weekly
The legacy notes span early 0.4–1.2 mg arms and later 1.6/2.4 mg weekly study arms.
Monthly Phase 2b arm4.8 mg monthly
Reported as monthly maintenance after a weekly study phase; investigational and not an approved regimen.
VESPER-2 T2D arm1.6 mg weekly
A distinct Phase 2b study arm in people with type 2 diabetes, not a class-wide amount.
Half-life & effect duration
- Half-life in the body
- Under-the-skin injection · sponsor estimateAbout 380 hours — roughly 15–16 days
- Felt duration people report
- During trial participationLess food noise and earlier fullness across 5 weeks
- Other sensationsOccasional fullness and heartburn after fatty meals
Cycles people discuss
The profile describes weekly study phases and a monthly-maintenance study design. These are trial schedules, not a community cycle or an endorsed transition plan.
Timing
Study schedules include weekly administration and, in separate maintenance designs, once-monthly administration after weekly titration. These are protocol-specific schedules, not an established community routine.
Stacks
Mental compare: weekly sema/tirz vs a monthly calendar.
Watch for
GI events in sponsor trials: Nausea, vomiting and diarrhea were reported; cross-trial analyst claims that GI effects are “louder than tirz” are not head-to-head evidence.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
Sponsor-reported human terminal half-life was about 380 hours, or roughly 15–16 days.
The long tail was reported alongside low PK variability and supports investigation of weekly and monthly regimens.
Preliminary sponsor filing rather than a peer-reviewed full PK paper; not an approved dosing interval or a felt-effect duration.
- Metsera Form 424B4 — MET-097i clinical data (opens in a new tab)MET-097i sections around the first-in-human SAD results and Figure 18: observed subcutaneous half-life approximately 380 hours (15–16 days), participant population and PK variability.Sponsor securities filing with preliminary program data; not a peer-reviewed full PK report and not a consumer-use source.
Felt duration people report
No dependable within-week or monthly felt-duration window is established.
The account described less food noise and earlier satiety over five weeks, with occasional fullness and heartburn after fatty meals.
Single relayed account, blinded assignment, no dose attribution, no within-dose timing and no monthly exposure.
- Berobenatide in VESPER-4 — community experience report (opens in a new tab)Participant-account paragraphs: weekly blinded VESPER-4 start, five-week weight change, less food noise, early satiety, fullness and heartburn after fatty meals.Relayed and AI-assisted community article; one blinded participant, unknown treatment assignment, no dose verification or direct follow-up thread.
Other context in this card
- Pfizer VESPER Phase 2b results announcement (opens in a new tab)Program overview and VESPER-1/2/3 sections, including 2.4 mg weekly and VESPER-2 type 2 diabetes study context.Sponsor press release; selected topline outcomes rather than a complete peer-reviewed dataset.
What people say
- The calendar: Monthly maintenance is the only reason this name beats a dozen other GLP-1s in 2026 chats. forum
- Weekly high (VESPER-1 extension talk): ~15.9% at week 60 of the overall story on 2.4 mg weekly, no plateau in that slice. trial
- Monthly (VESPER-3): Up to 12.3% placebo-adjusted at 28 weeks on 4.8 mg monthly after a weekly climb. trial
- T2D (VESPER-2): Weight plus A1C — 1.6 mg weekly ~2.2% A1C drop vs 0.2% placebo at 28 weeks in the summaries. trial
Doses people talk about
- No label. forum
- Weekly finding: 0.4–1.2 mg, later 1.6 / 2.4 mg weekly in extensions. trial
- Monthly maintenance quoted: 4.8 mg once a month after weekly titration. trial
- VESPER-2 T2D trial arm: 1.6 mg weekly in the Phase 2b type 2 diabetes study; not a class-wide amount or an approved regimen. trial
- Phase 3 monthly (VESPER-6) is the confirmatory design. trial
How it may feel
- Participant account: One person in blinded weekly VESPER-4 reported less food noise and earlier satiety across the first five weeks, plus occasional fullness and heartburn after fatty meals. Treatment assignment was unknown, and this does not establish a monthly or week-3 pattern. forum
- Import a GLP-1 start: Nausea, vomit, diarrhea, constipation on the way up. Analysts said VESPER GI looked busier than Zepbound’s packages and monthly-arm dropouts touched ~21% in one read. trial
- Monthly transition: The experiment is “can you stretch the shot without the stomach exploding.” Mild–moderate GI, no severe nausea/vomit in some monthly arms per company. trial
Cycles people discuss
- Not a 4-week blast. forum
- Weekly climb, then monthly hold in the 2b story. trial
Timing
- Why monthly is even a sentence: That stretched tail. forum
- Human PK: In the sponsor's first-in-human single-ascending-dose study, subcutaneous berobenatide had an observed terminal half-life of about 380 hours (about 15–16 days). This preliminary sponsor result is not a consumer dosing interval. trial
More on what it is
- Why people talk about it: “One shot a month.” ADA 2026 VESPER package: high weekly ~16% by ~60 weeks; monthly 4.8 mg ~12.3% placebo-adjusted at 28 weeks. Instagram already says the name next to Ozempic. forum
- Feel-log honesty: Consumer diaries are basically zero. GI tables + class GLP feel. forum
- What it is: Pfizer’s long-acting GLP-1 peptide (bought with Metsera as MET-097i). Weekly or monthly SC in Phase 2b. Phase 3 VESPER-6 monthly is enrolling in 2026 talk. Not a dual. Not orforglipron (that is a pill). trial
- How it works: Biased long GLP-1 agonist — same satiety class, stretched PK. trial
- Evidence: VESPER-1/2/3 Phase 2b (weekly and monthly, with and without T2D). trial
Stacks
- Mental compare: weekly sema/tirz vs a monthly calendar. forum
- Solo GLP-1 in VESPER. trial
Storage notes
- No community SOP. forum
Watch for
- Unapproved. forum
- Not a dual / not a pill. forum
- GI events in sponsor trials: Nausea, vomiting and diarrhea were reported; cross-trial analyst claims that GI effects are “louder than tirz” are not head-to-head evidence. trial
- Monthly-arm dropouts ~21% in one VESPER read — the hang-up. trial
Evidence mix
More trial/lab tags than forum tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.